Janssen Pharmaceuticals Investor Presentation — August 2018

Document content

MARINER & COMMANDER HF

CLINICAL TRIAL RESULTS

August 27, 2018Presenters

3James List, M.D., Ph.D.

Global Therapeutic Area Head,

Cardiovascular & Metabolism

Janssen Research & Development, LLC

Cardiovascular & Metabolism

Janssen Pharmaceuticals, Inc.Cautionary Note on Forward -looking Statements

4This webcast contains “forward -looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future

operating and financial performance, product development, market position and business strategy. The viewer is cautioned not to rely on these forward -looking

statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate o r known or unknown risks or

uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. R isks and uncertainties include, but are

not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including techn ological advances, new products and

patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinic al success and obtaining regulatory

approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expir ations; the ability of the company to

successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; ma nufacturing difficulties or delays,

internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government

action, including related to product liability claims; changes to applicable laws ,andregulations, including tax laws and global health care reforms; trends toward

health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; f inancial instability of international

economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; and th e potential failure to meet

obligations in compliance agreements with government bodies. A further list and descriptions of these risks, uncertainties an d other factors can be found in Johnson

& Johnson's Annual Report on Form 10 -K for the fiscal year ended December 31, 2017, including in the sections captioned “Caution ary Note Regarding Forward -

Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report son Form 10 -Q,and in the company’s subsequent